BibTex RIS Kaynak Göster
Yıl 2017, Cilt: 34 Sayı: 3, 206 - 211, 01.05.2017

Öz

Kaynakça

  • 1. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007;370:741-50.
  • 2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. Plos Med 2006;3:e442.
  • 3. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD Updated 2015. http:// www.goldcopd.org/uploads/users/files/GOLD_Report_2015_Feb18. pdf.
  • 4. Department of Health and Human Services Centers for Disease Control and Prevention: National Immunization Program Advisory Committee on Immunization Practices, 29-30 June 2006; Atlanta, GA. Record of the Proceedings. Available from: http://www.michigan.gov/documents/mdch/ AcipMinJun06_FB100.
  • 5. Chiatti C, Barbadoro P, Marigliano A, Ricciardi A, Di Stanislao F, Prospero E. Determinants of influenza vaccination among the adult and older Italian population with chronic obstructive pulmonary disease: a secondary analysis of the multipurpose ISTAT survey on health and health care use. Hum Vaccin 2011;7:1021-5.
  • 6. Ciblak MA. Grip Platformu. Influenza vaccination in Turkey: prevalence of risk groups, current vaccination status, factors influencing vaccine uptake and steps taken to increase vaccination rate. Vaccine 2013;31:518- 23.
  • 7. Cimen P, Unlu M, Kirakli C, Katgi N, Ucsular FD, Ayranci A, et al. Should Patients With COPD Be Vaccinated? Respir Care 2015;60:239-43.
  • 8. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease.GOLD Updated 2013. http://www. goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20. pdf
  • 9. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46.
  • 10. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999;54:581-86.
  • 11. Arinez-Fernandez MC, Carraco-Garrido P, Garcia-Carballo M, Hernandez-Barrera V, de Miguel AG, Jimenez-Garcia R. Determinants of pneumococcal vaccination among patients with chronic obstructive pulmonary disease in Spain. Hum Vaccin 2006;2:99-104.
  • 12. Vandenbos F, Gal J, Radicchi B. Vaccination coverage against influenza and pneumococcus for patients admitted to a pulmonary care service. Rev Mal Respir 2013;30:746-51.
  • 13. Biberoğlu K. Haydi Büyükler Aşıya. Actual Med 2006;14:18-26
  • 14. Montserrat-Capdevila J, Godoy P, Marsal JR, Cruz I, Solanes M. Effectiveness of influenza vaccination in preventing hospital admission due to exacerbations of chronic obstructive pulmonary disease. Enferm Infecc Microbiol Clin 2014;32:70-5.
  • 15. Damiani G, Federico B, Visca M, Agostini F, Ricciardi W. The impact of socioeconomic level on influenza vaccination among Italian adults and elderly: a cross-sectional study. Prev Med 2007;45:373-9

Influenza and Pneumonia Vaccination Rates and Factors Affecting Vaccination among Patients with Chronic Obstructive Pulmonary Disease

Yıl 2017, Cilt: 34 Sayı: 3, 206 - 211, 01.05.2017

Öz

Background: Influenza and pneumococcal vaccinations are recommended in chronic obstructive pulmonary disease patients to decrease associated risks at all stages. Although the prevalence of chronic obstructive pulmonary disease is high in our country, as previously reported, vaccination rates are low. Aims: To assess the vaccination rates of chronic obstructive pulmonary disease patients and factors that may affect these. Study Design: Multi-centre cross-sectional study. Methods: Patients admitted to the chest diseases clinics of six different centres between 1 February 2013 and 1 January 2014 with a pre-diagnosis of Chronic obstructive pulmonary disease according to the Global initiative for chronic obstructive lung disease criteria, who were in a stable condition were included in the study. The survey, which included demographic characteristics, socio-economic status, severity of disease and vaccination information, was first tested on a small patient population before the study. The survey was completed by the investigators after obtaining written informed consent. Results: The average age of the 296 included patients was 66.3±9.3 years and 91.9% were male. Of these, 36.5% had the influenza vaccination and 14.1% had the pneumococcal vaccination. The most common reason for not being vaccinated was ‘no recommendation by doctors’: 57.2% in the case of influenza vaccinations, and 46.8% in the case of pneumococcal vaccinations. Both vaccination rates were significantly higher in those patients with comorbidities (influenza vaccination p<0.001; pneumococcal vaccination p=0.06). There was no significant correlation with age, gender, smoking and severity of disease (p>0.05). Vaccination rates were significantly higher in those with a white-collar occupation and higher education level, and who presented to a university hospital (p<0.001). Conclusion: Medical professionals do not request vaccinations as often as the International Guidelines suggest for chronic obstructive pulmonary disease patients. Awareness of the importance of these vaccinations among both doctors and patients needs to be addressed.

Kaynakça

  • 1. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007;370:741-50.
  • 2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. Plos Med 2006;3:e442.
  • 3. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD Updated 2015. http:// www.goldcopd.org/uploads/users/files/GOLD_Report_2015_Feb18. pdf.
  • 4. Department of Health and Human Services Centers for Disease Control and Prevention: National Immunization Program Advisory Committee on Immunization Practices, 29-30 June 2006; Atlanta, GA. Record of the Proceedings. Available from: http://www.michigan.gov/documents/mdch/ AcipMinJun06_FB100.
  • 5. Chiatti C, Barbadoro P, Marigliano A, Ricciardi A, Di Stanislao F, Prospero E. Determinants of influenza vaccination among the adult and older Italian population with chronic obstructive pulmonary disease: a secondary analysis of the multipurpose ISTAT survey on health and health care use. Hum Vaccin 2011;7:1021-5.
  • 6. Ciblak MA. Grip Platformu. Influenza vaccination in Turkey: prevalence of risk groups, current vaccination status, factors influencing vaccine uptake and steps taken to increase vaccination rate. Vaccine 2013;31:518- 23.
  • 7. Cimen P, Unlu M, Kirakli C, Katgi N, Ucsular FD, Ayranci A, et al. Should Patients With COPD Be Vaccinated? Respir Care 2015;60:239-43.
  • 8. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease.GOLD Updated 2013. http://www. goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20. pdf
  • 9. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46.
  • 10. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999;54:581-86.
  • 11. Arinez-Fernandez MC, Carraco-Garrido P, Garcia-Carballo M, Hernandez-Barrera V, de Miguel AG, Jimenez-Garcia R. Determinants of pneumococcal vaccination among patients with chronic obstructive pulmonary disease in Spain. Hum Vaccin 2006;2:99-104.
  • 12. Vandenbos F, Gal J, Radicchi B. Vaccination coverage against influenza and pneumococcus for patients admitted to a pulmonary care service. Rev Mal Respir 2013;30:746-51.
  • 13. Biberoğlu K. Haydi Büyükler Aşıya. Actual Med 2006;14:18-26
  • 14. Montserrat-Capdevila J, Godoy P, Marsal JR, Cruz I, Solanes M. Effectiveness of influenza vaccination in preventing hospital admission due to exacerbations of chronic obstructive pulmonary disease. Enferm Infecc Microbiol Clin 2014;32:70-5.
  • 15. Damiani G, Federico B, Visca M, Agostini F, Ricciardi W. The impact of socioeconomic level on influenza vaccination among Italian adults and elderly: a cross-sectional study. Prev Med 2007;45:373-9
Toplam 15 adet kaynakça vardır.

Ayrıntılar

Diğer ID JA76RR22AU
Bölüm Araştırma Makalesi
Yazarlar

Ülkü Aka Aktürk Bu kişi benim

Aslı Görek Dilektaşlı Bu kişi benim

Aysun Şengül Bu kişi benim

Banu Musaffa Salepçi Bu kişi benim

Nuray Oktay Bu kişi benim

Mustafa Düger Bu kişi benim

Hale Arık Taşyıkan Bu kişi benim

Nagihan Durmuş Koçak Bu kişi benim

Yayımlanma Tarihi 1 Mayıs 2017
Yayımlandığı Sayı Yıl 2017 Cilt: 34 Sayı: 3

Kaynak Göster

APA Aktürk, Ü. A., Dilektaşlı, A. G., Şengül, A., Salepçi, B. M., vd. (2017). Influenza and Pneumonia Vaccination Rates and Factors Affecting Vaccination among Patients with Chronic Obstructive Pulmonary Disease. Balkan Medical Journal, 34(3), 206-211.
AMA Aktürk ÜA, Dilektaşlı AG, Şengül A, Salepçi BM, Oktay N, Düger M, Taşyıkan HA, Koçak ND. Influenza and Pneumonia Vaccination Rates and Factors Affecting Vaccination among Patients with Chronic Obstructive Pulmonary Disease. Balkan Medical Journal. Mayıs 2017;34(3):206-211.
Chicago Aktürk, Ülkü Aka, Aslı Görek Dilektaşlı, Aysun Şengül, Banu Musaffa Salepçi, Nuray Oktay, Mustafa Düger, Hale Arık Taşyıkan, ve Nagihan Durmuş Koçak. “Influenza and Pneumonia Vaccination Rates and Factors Affecting Vaccination Among Patients With Chronic Obstructive Pulmonary Disease”. Balkan Medical Journal 34, sy. 3 (Mayıs 2017): 206-11.
EndNote Aktürk ÜA, Dilektaşlı AG, Şengül A, Salepçi BM, Oktay N, Düger M, Taşyıkan HA, Koçak ND (01 Mayıs 2017) Influenza and Pneumonia Vaccination Rates and Factors Affecting Vaccination among Patients with Chronic Obstructive Pulmonary Disease. Balkan Medical Journal 34 3 206–211.
IEEE Ü. A. Aktürk, “Influenza and Pneumonia Vaccination Rates and Factors Affecting Vaccination among Patients with Chronic Obstructive Pulmonary Disease”, Balkan Medical Journal, c. 34, sy. 3, ss. 206–211, 2017.
ISNAD Aktürk, Ülkü Aka vd. “Influenza and Pneumonia Vaccination Rates and Factors Affecting Vaccination Among Patients With Chronic Obstructive Pulmonary Disease”. Balkan Medical Journal 34/3 (Mayıs 2017), 206-211.
JAMA Aktürk ÜA, Dilektaşlı AG, Şengül A, Salepçi BM, Oktay N, Düger M, Taşyıkan HA, Koçak ND. Influenza and Pneumonia Vaccination Rates and Factors Affecting Vaccination among Patients with Chronic Obstructive Pulmonary Disease. Balkan Medical Journal. 2017;34:206–211.
MLA Aktürk, Ülkü Aka vd. “Influenza and Pneumonia Vaccination Rates and Factors Affecting Vaccination Among Patients With Chronic Obstructive Pulmonary Disease”. Balkan Medical Journal, c. 34, sy. 3, 2017, ss. 206-11.
Vancouver Aktürk ÜA, Dilektaşlı AG, Şengül A, Salepçi BM, Oktay N, Düger M, Taşyıkan HA, Koçak ND. Influenza and Pneumonia Vaccination Rates and Factors Affecting Vaccination among Patients with Chronic Obstructive Pulmonary Disease. Balkan Medical Journal. 2017;34(3):206-11.